Cargando…
Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases
Reports of Bone Scan Index (BSI) calculations as imaging biomarkers to predict survival in patients with metastatic castration-resistant prostate cancer (mCRPC) have been mainly from retrospective studies. To evaluate the effectiveness of enzalutamide (ENZ) in Japanese patients with mCRPC and bone m...
Autores principales: | Hirano, Hisashi, Nagata, Masayoshi, Nagaya, Naoya, Nakamura, So, Ashizawa, Takeshi, Lu, Yan, Kawano, Haruna, Kitamura, Kosuke, Sakamoto, Yoshiro, Fujita, Kazuhiko, Isobe, Hideyuki, Tsujimura, Akira, Muto, Satoru, Horie, Shigeo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226993/ https://www.ncbi.nlm.nih.gov/pubmed/37248346 http://dx.doi.org/10.1038/s41598-023-35790-5 |
Ejemplares similares
-
Skeleton Segmentation on Bone Scintigraphy for BSI Computation
por: Yu, Po-Nien, et al.
Publicado: (2023) -
Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer
por: Ashizawa, Takeshi, et al.
Publicado: (2022) -
Transcription factor 4 expression in circulating tumor cells from castration‐resistant prostate cancer
por: Nagaya, Naoya, et al.
Publicado: (2021) -
Bone Scintigraphy
por: Galasko, D.
Publicado: (1982) -
Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer
por: Nagaya, Naoya, et al.
Publicado: (2020)